Nova Publishers
My Account Nova Publishers Shopping Cart
HomeBooksSeriesJournalsReference CollectionseBooksInformationSalesImprintsFor Authors
            
  Top » Catalog » Books » Medicine » Immune Disorders » My Account  |  Cart Contents  |  Checkout   
Quick Find
  
Use keywords to find the product you are looking for.
Advanced Search
What's New? more
The Evolution of Love
$207.00
Shopping Cart more
0 items
Information
Shipping & Returns
Privacy Notice
Conditions of Use
Contact Us
Bestsellers
01.Molecular Mechanisms of Tobacco-Induced Diseases
02.Women and Multiple Sclerosis
03.Autoantibodies Research Progress
04.Lupus: Symptoms, Treatment and Potential Complications
05.Systemic Lupus Erythematosus Research Developments
06.Acute Rejection: Risk Factors, Management and Complications
07.Immunogenicity
08.New Research on Innate Immunity
09.Autoimmune Diseases: Symptoms, Diagnosis and Treatment
10.Autoimmune Disorders: Symptoms, Diagnosis and Treatment
Notifications more
NotificationsNotify me of updates to Old and Novel Humoral Biomarkers of Autoimmune Myasthenia Gravis
Tell A Friend
 
Tell someone you know about this product.
Old and Novel Humoral Biomarkers of Autoimmune Myasthenia Gravis
Retail Price: $95.00
10% Online Discount
You Pay:

$85.50
Authors: Davide Giacomo Corda, M.D., Giovanni Andrea Deiana, Giannina Arru, Giovanni Masala and GianPietro Sechi, M.D. (Department of Clinical Surgery and Experimental Medicine, University of Sassari, Sassari, Italy) 
Book Description:
Autoimmune Myasthenia Gravis (MG) is mediated by pathogenic autoantibodies to components of the postsynaptic muscle endplate at the neuromuscular junction. Due to the clinical heterogeneity of the disease, there is a great need for objective biomarkers for diagnostic as well as therapeutic purposes. Humoral biomarkers of MG can be divided into two categories: 1) autoantibodies; and 2) other immune-related molecules including inflammatory proteins, microRNA, HLA genes.
Regarding autoantibodies, the radio immuno assay (RIA) allows for the detection of IgG1 and IgG3 antibodies directed against the nicotinic acetylcholine receptors (AChRAb) in 85% of the patients with generalized MG, but only in 50% of those with the ocular form. Treatment with acetylcholinesterase inhibitors is very helpful, although immunosuppressive therapy is frequently necessary. Thymoma or thymic hyperplasia can occur, implicating surgery. In AChRAb negative generalized MG patients, a very variable percentage has IgG4 antibodies towards muscle specific tyrosine kinase (MuSKAb): typically, bulbar weakness is the first symptom often associated with neck and respiratory involvement. Acetylcholinesterase inhibitors are less effective and induce frequent side effects; first and second line suppressive treatments are commonly required. More rarely, IgG towards low density lipoprotein receptor-related protein 4 (Lrp4Ab), agrin or cortactin are detected: if there are not associated AChRAb or MuSKAb, often patients present with milder forms of MG. Few patients have been demonstrated positive to AChRAb or to other autoantibodies with the more sensitive cell based assay. Finally, titin and ryanodine receptor antibodies can occur in association with AChRAb MG, indicating the possibility of thymoma or, in the context of late-onset myasthenia gravis, severe disease with a need for long-term immunosuppression and no response to thymectomy.
In regards to immune-related molecules, two recent studies reported increased serum levels of a proliferation-inducing ligand (APRIL), cytokines IL-19, IL-20, IL-28A and IL-35, matrix metalloproteinase 10 (MMP-10), which is a member of the metalloproteinase family, transforming growth factor alpha (TGF-α), a growth factor that has important roles for epithelial proliferation and differentiation, and the extracellular newly identified receptor for advanced glycation end-products binding protein (EN-RAGE, also known as protein S100-A12), a protein that binds to calcium, zinc and copper. These three last proteins are involved in the cell cycle progression and differentiation, and play multiple roles in immunity response. Circulating microRNAs (miRNA) have been reported to be potential biomarkers in some MG patients; in particular, miR-150-5p and miR-21-5p for AChRAb MG and the let7 family for MuSKAb MG. These miRNA are involved in the development of T- and B-cell autoimmune responses. Some HLA associations have been reported, such as DR3-B8-A1 in early onset AChRAb MG and DR14, DR16 and DQ5 in MuSKAb MG.
Characterization of novel humoral biomarkers is a topic of great importance for diagnosis, prognosis and therapy of the various subgroups of MG, although it remains a partially fulfilled clinical need. Other serum biomarkers are currently the subject of active research. (Nova Medicine and Health)

Table of Contents:
Abstract

Chapter 1. Introduction
1.1. Autoimmune Myasthenia Gravis
1.2. Pathogenesis of MG: Immune System
1.3. Pathogenesis of MG: Thymus
1.4. Humoral Biomarkers for MG

Chapter 2. Acetylcholine Receptor Antibodies

Chapter 3. Muscle-Specific Receptor Tyrosine Kinase Antibodies

Chapter 4. Low-Density Lipoprotein Receptor-Related Protein 4 Antibodies

Chapter 5. Striational Antibodies
5.1. Introduction
5.2. Rapsyn Antibodies
5.3. Titin Antibodies
5.4. Ryanodine Receptor Autoantibodies
5.5 Kv1.4 Autoantibodies
5.6. Conclusion

Chapter 6. Agrin Antibodies

Chapter 7. Collagen Q Antibodies

Chapter 8. Cortactin Antibodies

Chapter 9. Cytokines, Crmp5, Presynaptic Voltage-Gated Calcium Channel Antibodies of the P/Q and N-Type, Glutamic Acid Decarboxylase 65 and Other Autoantibodies

Chapter 10. Biomarkers Related to B Lymphocyte
10.1. Activated B Cells and Plasma Cells
10.2. Regulatory B Cells [300]

Chapter 11. Biomarkers Related to T Lymphocyte
11.1. T Cell Receptor
11.2. T Helper Cells
11.3. Follicular CD4+ Th Cells
11.4. CD4+CD25+ Regulatory T Cells

Chapter 12. Inflammatory Proteins

Chapter 13. Serum Albumin, Uric Acid and Other Antioxidants as Biomarkers in MG

Chapter 14. Epigenetic Markers

Chapter 15. Genetic DNA Markers of MG

Chapter 16. Sex Hormones, Conclusion, References

   Series:
      Immunology and Immune System Disorders
   Binding: Softcover
   Pub. Date: 2018 - September
   ISBN: 978-1-53613-836-8
   Status: AN
  
Status Code Description
AN Announcing
FM Formatting
PP Page Proofs
FP Final Production
EP Editorial Production
PR At Prepress
AP At Press
AV Available
  
Special Focus Titles
01.Heart Failure: What a Non-Heart Failure Specialist Needs to Know
02.Bottle-Feeding: Perceptions, Practices, and Health Outcomes
03.Between Success and Failure: Assessment of Aspirations and Risk (CD Included)
04.Understanding Left and Right: An Illustrated Guide to the Political Divide
05.Phytoremediation: Methods, Management and Assessment
06.“Waste-to-Profit” (W-t-P): Value added Products to Generate Wealth for a Sustainable Economy. Volume 1
07.The Impact and Implications of Crisis: A Comprehensive Approach Combining Elements of Health and Society
08.When "We" Are Stressed: A Dyadic Approach to Coping with Stressful Events
09.The Man Brand: Why Public Campaigns Hide Half of Intimate Partner Violence
10.The Life of Abraham Lincoln: Drawn from Original Sources and Containing Many Speeches, Letters and Telegrams Hitherto Unpublished. Volume One
11.Life of Charles Dickens
12.The Inventions and Discoveries of the World’s Most Famous Scientists

Nova Science Publishers
© Copyright 2004 - 2018

Old and Novel Humoral Biomarkers of Autoimmune Myasthenia Gravis